DNA damage proteins and response to therapy in head and neck cancer

Molecular Determinants of Head and Neck Cancer

Volumn , Issue , 2014, Pages 259-282

  Mehra, Ranee ^a   Serebriiskii, Ilya G ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cisplatin adducts; DNA repair; Radiation

Indexed keywords

EID: 84927973945     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8815-6_13     Document Type: Chapter

References (105)

1. Sturgis EM, Clayman GL, Guan Y, Guo Z, Wei Q. DNA repair in lymphoblastoid cell lines from patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):185-90.
2. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis. 2000 Dec;21(12):2219-23.
3. Sturgis EM, Castillo EJ, Li L, et al. XPD/ERCC2 EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. Oral Oncol. 2002 Jul;38(5):475-77.
4. Jones NR, Spratt TE, Berg AS, Muscat JE, Lazarus P, Gallagher CJ. Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. Cancer Epidemiol. 2011 Apr;35(2):175-81.
5. Jelonek K, Gdowicz-Klosok A, Pietrowska M, et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51(3):343-52.
6. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 15 Apr;2005;65(8):3328-35.
7. Sak A, Grehl S, Engelhard M, et al. Long-term in vivo effects of cisplatin on gamma-H2AX foci signaling in peripheral lymphocytes of tumor patients after irradiation. Clin Cancer Res. Apr 15 2009;15(8):2927-34.
8. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000 Nov 1;18(21 Suppl):47S-53S.
9. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):427-33.
10. Rusin P, Walczak A, Zwierzchlejska A, et al. DNA damage and repair of head and neck cancer cells after radio-and chemotherapy. Zeitschrift fur Naturforschung. 2009 Jul-Aug;64(7-8):601-10.
11. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27.
12. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54.
13. Adelstein DJ, LiY, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8.
14. Blommaert FA, Floot BG, van Dijk-Knijnenburg HC, et al. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA. Chem Biol Interact. 1998 Jan 30;108(3):209-25.
15. ForastiereAA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52.
16. Cha HJ, Yim H. The accumulation of DNA repair defects is the molecular origin of carcinogenesis. Tumour Biol. 2013 Aug 2.
17. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000 Jun;6(6):2166-74.
18. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomaviruspositive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-69.
19. KimYJ, WilsonDM3rd. Overviewof base excision repair biochemistry. Curr Mol Pharmacol. 2012 Jan;5(1):3-13.
20. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J. 2001 Nov 15;20(22):6530-39.
21. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNAdependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963 Apr 2;11:39-43.
22. Uchida K, Miwa M. Poly(ADP-ribose) Polymerase: structural conservation among different classes of animals and its implications. Mol Cell Biochem. 1994 Sep;138(1-2):25-32.
23. Fisher AE, Hochegger H, Takeda S, Caldecott KW. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol. 2007 Aug;27(15):5597-605.
24. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14;434(7035):917-21.
25. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14;434(7035):913-17.
26. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011 Oct 11;105(8):1114-22.
27. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochem. 1996 Aug 635(31):10004-13.
28. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinog. 1993 Oct;14(10):2177-80.
29. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science. 1999 May 7;284(5416):958-61.
30. Iyama T, Wilson DM 3rd. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair. 2013 Aug;12(8):620-36.
31. Enzlin JH, Scharer OD. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J. 2002 Apr 15;21(8):2045-53.
32. Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11236-41.
33. Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem. 1997 Feb 7;272(6):3833-37.
34. Jaspers NG, RaamsA, Silengo MC, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007 Mar;80(3):457-66.
35. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008 Aug;28(16):5082-92.
36. Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008 Jul-Aug;129(7-8):391-407.
37. Misteli T, Soutoglou E. The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol. 2009 Apr;10(4):243-54.
38. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003 Aug;23(16):5706-15.
39. Fernandez-Capetillo O, Celeste A, Nussenzweig A. Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle. 2003 Sep-Oct;2(5):426-27.
40. Lee SA, Baker MD. Analysis of DNA repair and recombination responses in mouse cells depleted for Brca2 by SiRNA. DNA Repair. 2007 Jun 1;6(6):809-17.
41. SancarA, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39-85.
42. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell. 1993 Jan 15;72(1):131-42.
43. Yang J, YuY, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis. 2003 Oct;24(10):1571-80.
44. Grompe M, D' Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet. 2001 Oct 1;10(20):2253-59.
45. Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair ofWatson and Crick DNA crosslinks. Nature. 2013 Jan 17;493(7432):356-63.
46. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):106-12.
47. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003 Feb 15;101(4):1249-56.
48. Hoskins EE, Morreale RJ, Werner SP, et al. The fanconi anemia pathway limits human papillomavirus replication. J Virol. 2012 Aug;86(15):8131-38.
49. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21.
50. Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirusassociated malignancies. J Natl Cancer Inst. 2003 Nov 19;95(22):1648-50.
51. Orelli B, McClendon TB, Tsodikov OV, Ellenberger T, Niedernhofer LJ, Scharer OD. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. J Biol Chem. 2009 Feb 5;285(6):3705-12.
52. Murray D, Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxiccell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res. 1996 Dec 2;364(3):217-26.
53. Bhagwat N, Olsen AL, Wang AT, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol. 2009 Dec;29(24):6427-37.
54. Thyagarajan B, Campbell C. Elevated homologous recombination activity in fanconi anemia fibroblasts. J Biol Chem. 1997 Sep 12;272(37):23328-33.
55. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett. 2010 Jun 1;292(1):73-79.
56. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002 Jul;8(7):2286-91.
57. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91.
58. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007 Jun 14;356(24):2538-2540; author reply 2540-1.
59. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013 Mar 21;368(12):1101-10.
60. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8;99(1):167-72.
61. Fountzilas G, Bamias A, Kalogera-Fountzila A, et al. Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable nonnasopharyngeal carcinoma of the head and neck. Anticancer Res. 2009 Feb;29(2):529-38.
62. Seiwert TY, Cohen EE, Wang X, et al. Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy. J Clin Oncol. 2008;26(15S): 6003.
63. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007 Jul 1;13(13):3855-59.
64. KohY, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009 Aug;20(8):1414-19.
65. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009 Sep 1;69(17):6831-38.
66. Mehra R, Zhu F, Yang DH, et al. Quantification of excision repair cross complementing group 1 (ERCC1) and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013 Oct 2.
67. Austin M, Schmidt R, Parvathaneni U, et al. Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib:A phase II randomized trial. Paper presented at: ASCO2012.
68. Bauman JE, Austin MC, Schmidt R, et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013 Oct 15;109(8):2096-105.
69. Hao D, Lau HY, Eliasziw M, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck. 2011 Jun;34(6):785-91.
70. Gustavson MD, Bourke-Martin B, Reilly DM, et al. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated quantitative analysis. Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):329-37.
71. Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol. 2009;520:163-75.
72. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006 Dec;17(12):1818-25.
73. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007 Jul 1;25(19):2747-54.
74. Joshi MB, ShirotaY, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005 Mar 15;11(6):2215-21.
75. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994 Aug;94(2):703-8.
76. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul 1;25(19):2741-46.
77. Bepler G, Williams C, Schell MJ, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced nonsmall-cell lung cancer. J Clin Oncol. 2013 Jul 1;31(19):2404-12.
78. Vermeulen J, De Preter K, Lefever S, et al. Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res. 2011 May;39(9):e63.
79. Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011 Aug 15;17(16):5513-22.
80. Koberle B, Ditz C, Kausch I, Wollenberg B, Ferris RL, Albers AE. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. Int J Oncol. 2010 May;36(5):1277-84.
81. Ang MK, Patel MR, Yin XY, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2011 Oct 15;17(20):6542-52.
82. Schwartz JL, Mustafi R, Beckett MA, Weichselbaum RR. DNA double-strand break rejoining rates, inherent radiation sensitivity and human tumour response to radiotherapy. Br J Cancer. 1996 Jul;74(1):37-42.
83. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May;28(5):1113-19.
84. Shin KH, Kang MK, Kim RH, Kameta A, Baluda MA, Park NH. Abnormal DNA end-joining activity in human head and neck cancer. Int J Mol Med. 2006 May;17(5):917-24.
85. Pavon MA, Parreno M, Leon X, et al. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. Int J Cancer. 2008 Sep 1;123(5):1068-79.
86. Moeller BJ, Yordy JS, Williams MD, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 1;17(7):2035-43.
87. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006 Sep 10;24(26):4333-39.
88. Zhong S, Nukui T, Buch S, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429-37.
89. Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol. 2011 Jun;99(3):356-61.
90. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nature Genet. 2013 Mar;45(3):279-84.
91. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. Oct 2012;3(10):1194-1203.
92. de Miranda NF, Peng R, Georgiou K, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med. 2013 Aug 26;210(9):1729-42.
93. Sheikh Ali MA, Gunduz M, Nagatsuka H, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 2008 Aug;99(8):1589-94.
94. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20;23(24):5568-77.
95. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.
96. Magne N, Fischel JL, Tiffon C, et al. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer. 2003 Aug 4;89(3):585-92.
97. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res. 2003 Apr;159(4):439-52.
98. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002 Jun;2(6):442-54.
99. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-tomesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4147-53.
100. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009 Jul 15;69(14):5820-28.
101. Yang MH, Chang SY, Chiou SH, et al. Overexpression of NBS1 induces epithelialmesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncog. 2007 Mar 1;26(10):1459-67.
102. Hsu DS, Lan HY, Huang CH, et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010 Sep 15;16(18):4561-71.
103. Zaidi S, McLaughlin M, Bhide SA, et al. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PloS One. 2012;7(4):e35436.
104. YadavA, Kumar B, TeknosTN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther. 2011 Jul;10(7):1241-51.
105. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 2011 Jun;99(3):331-8.